After adjustments for demographic characteristics, there was no statistically significant difference in MM incidence in TNF-α inhibitor users than in exclusive csDMARD users (HR 1.28, 95% CI 0.74–2.22) (Supplemental Table 3). Here, TNF is linked to Miyoshi myopathy.